Charles River Laboratories Intl. Inc vs Under Armour Inc Class A — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while Under Armour Inc Class A trades at $4.93 (market cap $2.07B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 6.9× Under Armour Inc Class A's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Under Armour Inc Class A for 99 Days on average.
| CRL | UAA | |
|---|---|---|
Market Cap | $14.23B | $2.07B |
Volume | 1,176,885 | 12,050,442 |
Sector | Health | Consumer Cyclical |
52-Week High | $310.77 | $8.14 |
52-Week Low | $149.93 | $4.17 |
Typical Hold Time | 33 Days | 99 Days |
Enterprise Value | $17.06B | $3.05B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298.00, down 0.77% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of -$144.34M for 2025. Analyst consensus is strongly positive with a $305.50 price target, and recent news highlights a strategic growth plan targeting 5%-7% revenue growth by 2030.
The stock's outlook is supported by strong analyst buy ratings and a clear growth strategy, but faces risks from negative profitability metrics and high valuation multiples. Investment opportunity hinges on successful execution of margin expansion and cost savings initiatives, while key risks include persistent net losses and competitive pressures in the healthcare services sector.
Under Armour (UAA) trades at $4.88, up 1.24% with a mixed technical outlook showing bullish moving averages but neutral oscillators. The company faces fundamental challenges with negative net income margins (-9.99%) and ROE (-29.82%) despite beating Q2 2026 EPS estimates. Recent news highlights the company's brand transformation efforts amid softer demand, with management maintaining profitability outlook despite revenue cuts.
The stock presents a high-risk opportunity with analyst consensus pointing to 18.6% upside to the $5.79 price target. Key risks include persistent revenue weakness, negative cash flow trends, and competitive pressures. The 27% buy rating suggests cautious optimism, but investors need clear evidence of sustainable margin improvement and revenue stabilization for meaningful upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →